Clinical trials: Dermatologic Diseases
Atopic Dermatitis
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Assess the efficacy of several subcutaneous doses of nemolizumab in moderate-to-severe atopic dermatitis (AD) subjects with severe pruritus receiving TCS, who were not adequately controlled with topical treatments.
- Trial name
- NCT03100344
- Testing
- Nemolizumab
- Where
- 67 sites in United States, Australia and 4 more
- Volunteers
- 226 people
- Sponsor
- Galderma R&D
Breast Cancer
Study of Neoadjuvant Chemotherapy of Breast Cancer
The purpose of this study is to evaluate the pathological CR rate in breast and lymph nodes of a novel neoadjuvant regimen for invasive breast carcinoma.
- Trial name
- Neoadjuvant (NCT00830544)
- Testing
- Neoadjuvant chemotherapy, Chemotherapy
- Where
- Puerto Rico
- Volunteers
- 54 people
- Sponsor
- Auxilio Mutuo Cancer Center
Solid Tumors, Breast Cancer
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
The primary purpose(s) of this study is to determine the highest tolerated dose of tanespimycin and to determine anti-tumor activity (via objective response rate) of tanespimycin in patients with breast cancer who have not…
- Trial name
- NCT00773344
- Testing
- Tanespimycin
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Bristol-Myers Squibb
Wounds and Injuries, Cancer Pain
Benefits of Morphine Gel for Pain Reduction in Patients With Cancer Wounds
The goal of this clinical trial is to compare in compare pain reduction in patients with malignant wounds using morphine gel or lidocaine gel.
- Conditions
- Wounds and Injuries, Cancer Pain, Cancer, Breast, Cancer Head Neck
- Trial name
- MorphineGEL (NCT05800834)
- Testing
- Morphine Sulfate, Lidocaine Hcl 2% Jelly
- Where
- Brazil
- Volunteers
- 106 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Palmar-plantar Erythrodysesthesia (PPE)
Testing the Effectiveness of Henna on Managing PPE
The palmar-plantar erythrodysesthesia (PPE) is the only clinical adverse event that commonly occurs with capecitabine and/or pegylated liposomal doxorubicin treatment and it warrants special attention because it is the most…
- Trial name
- NCT01751893
- Testing
- Henna
- Where
- Cyprus
- Volunteers
- 56 people
- Sponsor
- Cyprus University of Technology
Breast Cancer, Mastectomy
Post-Operative Outcomes of Low Thermal Dissection vs. Traditional Electrosurgery
Low thermal dissection devices have been introduced as a tool to improve surgical outcomes. PlasmaBlade, a low thermal dissection device, has shown to be associated with effective cutting, and significantly lower temperature than…
- Conditions
- Breast Cancer, Mastectomy, Perfusion; Complications, Hemostasis
- Trial name
- NCT03711916
- Testing
- PlasmaBlade 3.0S
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Breast Cancer
Therapy Management With Nab-Paclitaxel in Daily Routine
Despite treatment improvements in breast cancer, a large number of patients still progress to the metastatic stage. Metastatic breast cancer patients have an extremely unfavorable prognosis.
- Trial name
- SERAPHINA (NCT02642406)
- Where
- 83 sites in Germany
- Volunteers
- 1,200 people
- Sponsor
- University Hospital Tuebingen
Malignant Melanoma
Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma
The purpose of this research study is to study a type of gene therapy treatment called plasmid electroporation. This type of treatment involves the injection of a gene into some melanoma tumors located near the surface of the…
- Trial name
- NCT00323206
- Testing
- IL-12p DNA, Intratumoral Electroporation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-small Cell Lung Cancer, Melanoma
PD-L1 Expression in Cancer (PECan Study).
Measurement of PD-L1 expression in cancer to monitor treatment response. A prospective non-blinded, single centre, single interventional arm diagnostic imaging study.
- Trial name
- PECan (NCT04436406)
- Testing
- [99mTc]-NM-01 SPECT/CT
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Breast Cancer
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
The purpose of this study is to microscopically examine breast cancer cells of pre-menopausal and post-menopausal women before and after exposure to one of the two commonly used breast cancer drugs, tamoxifen or fulvestrant.
- Trial name
- NCT02936206
- Testing
- Fulvestrant, Tamoxifen
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alopecia Areata
A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
This study is designed to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.
- Trial name
- NCT04784533
- Testing
- CTP-543
- Where
- 39 sites in United States
- Volunteers
- 317 people
- Sponsor
- Concert Pharmaceuticals
Breast Cancer, Prostate Cancer
The Association Between CBT-I Dose and Innate Immunity in Insomnia and Fatigue in Prostate Cancer Patients
The objective of this project is to test the association between Cognitive Behavioral Therapy for Insomnia dose (number of sessions), severity of cancer related fatigue, and levels of innate immunity biomarkers.
- Trial name
- NCT06604247
- Testing
- Cognitive Behavioral therapy for insomnia (CBT-I)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Multiple Myeloma, Melanoma
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
This is a first-in-human trial proposed to test HLA-A*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.
- Conditions
- Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
- Trial name
- NCT03399448
- Testing
- NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Pennsylvania
Alopecia Areata
A Study of LAD603 in Adults With Alopecia Areata
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA).
- Trial name
- NCT07311564
- Testing
- LAD603
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Almirall, S.A.
Breast Cancer
Melatonin Postoperative Sleep Study in Breast Cancer Patients
Primary Objective: To evaluate the impact of postoperative exogenous nocturnal melatonin supplementation on the early regulation of the sleep-wake cycle and its clinical impact (subjective improvement of the quality of sleep and…
- Trial name
- NCT00506064
- Testing
- Melatonin, Questionnaire
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Breast Cancer and Rehabilitation
Tai-Chi Exercise Reduces Fatigue in Breast Cancer Patients Undergoing Chemotherapy
Tai-Chi Exercise Reduces Fatigue in Breast Cancer Patients Undergoing Chemotherapy. The main question it aims to answer is: Does Tai-chi training reduce fatigue in breast cancer patients? Participants performed the exercise on…
- Trial name
- NCT07702409
- Testing
- Tai-chi, Daily Physical Activities
- Where
- Indonesia
- Volunteers
- 61 people
- Sponsor
- Chairul Huda
Breast Cancer
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in…
- Trial name
- INAVO123 (NCT06790693)
- Testing
- Inavolisib, CDK4/6i, Letrozole
- Where
- 242 sites in United States, Argentina and 18 more
- Volunteers
- 450 people
- Sponsor
- Hoffmann-La Roche
Vitiligo
Evaluating the Efficacy and Safety of Metformin in Vitiligo
Metformin modulates metabolism in multiple cell types and is currently used to reduce glucose levels and insulin resistance in diabetic patients.
- Trial name
- NCT05607316
- Testing
- Metformin Hydrochloride
- Where
- United States
- Sponsor
- University of Massachusetts, Worcester
Breast Cancer, Breast Carcinoma in Situ
Oncologic, Cosmetic and Patient Reported Outcomes in Value-Based Breast Surgery (OnCoPRO Value)
The study aspires to provide outcomes on surgery, quality of life and time-to-event outcomes following the development and validation of a standardised surgical assessment tool in a shared decision-making framework for patients…
- Conditions
- Breast Cancer, Breast Carcinoma in Situ, Breast Cancer Invasive, Breast Asymmetry
- Trial name
- OncoPROValue-1 (NCT06401304)
- Where
- 3 sites in Australia, Sweden and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Uppsala University
HER2 Positive Breast Cancer
A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
In the TROIKA study, the proposed biosimilar HD201 will be compared to its reference product Herceptin®. The aim of the study is to demonstrate equivalence of HD201 and Herceptin® in terms of efficacy, safety and pharmacokinetics.
- Trial name
- TROIKA (NCT03013504)
- Testing
- HD201, Herceptin, Docetaxel
- Where
- 15 sites in Belarus, Bulgaria and 11 more
- Volunteers
- 503 people
- Sponsor
- Prestige Biopharma Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.